|
|
Investor Relations
Agendia is a privately owned company that has raised funds in several investment rounds to develop and market its portfolio of in vitro diagnostic services. Original shareholders include the founders of Agendia and Stichting Fondsen Nederland that originated from the Netherlands Cancer Institute. For additional inquiries, please contact us at: investorrelations@agendia.com.
Financing Milestones
September 22, 2009
Agendia closed a series E financing round raising $23 million. The success of this round was aided by increasing U.S. demand for MammaPrint, as well as growing reimbursement. The proceeds will be used to accelerate U.S. commercialization and to bolster Agendia's strategic marketing and sales efforts as it brings MammaPrint to an ever increasing number of breast cancer patients.
August 28, 2007
Agendia raises €25 Million ($34M) in its fourth financing round, as ING Corporate Investments, one of the largest bank-insurers, becomes a substantial shareholder, joining existing investors, Van Herk Biotech B.V., Gilde Healthcare Partners B.V. and Global Life Science Ventures, who also participated. This financing round enables the company to further strengthen its position as a world leader in personalized medicine.
June 2, 2006
Agendia BV closes a third financing round with two of the largest biotechnology investors of The Netherlands - the Van Herk Group and Gilde Healthcare Partners. The funds raised will be used to accelerate development of microarray-based late stage products into diagnostic tests for breast cancer and other cancer types and to globally market the lead products, MammaPrint and CupPrint.
October 13, 2005
Agendia BV closes a second financing round with the Van Herk Group from The Netherlands. The funds raised will be used to accelerate development of microarray-based late stage products into diagnostic tests for other cancer types and to market the lead products, MammaPrint and CupPrint. The Van Herk Group joins Gilde Healthcare Partners B.V., Global Life Sciences Ventures, Germany, AXA Private Equity Venture as investors.
|
